AI In Biotechnology Market Trends Support A 24.1% CAGR Outlook Through The Forecast Period

The integration of artificial intelligence (AI) in biotechnology is rapidly transforming the industry, driving significant advancements in drug development, diagnostics, and personalized medicine. With vast amounts of biological data becoming available and innovative AI technologies being applied, this sector is set for remarkable expansion in the coming years. Let's explore the current market size, key drivers, major players, emerging trends, and the main segments shaping the AI in biotechnology market.

Projected Market Expansion of AI in Biotechnology
The AI in biotechnology market has experienced substantial growth recently, with its value expected to rise from $5.52 billion in 2025 to $6.87 billion in 2026. This represents a strong compound annual growth rate (CAGR) of 24.4%. The market's early expansion is largely driven by increased availability of biological data, the initial adoption of bioinformatics tools, escalating drug development costs, a growing demand for faster diagnostic methods, and the broadening scope of genomics research.
Looking ahead, the market is set to surge dramatically, reaching an estimated size of $16.32 billion by 2030 at a CAGR of 24.1%. This forecasted growth is fueled by progress in machine learning algorithms, wider implementation of precision medicine, heightened investments in AI within life sciences, the push for cost-effective drug development methods, and the fusion of AI with laboratory automation. Key trends anticipated include AI-powered drug discovery, predictive genomics, automated clinical trial enhancements, AI-supported diagnostics, and data-driven personalized treatments.

Leading Corporations Driving the AI in Biotechnology Industry
Several prominent companies are at the forefront of the AI in biotechnology market, including Google LLC, Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., International Business Machines Corporation (IBM), Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Roivant Sciences Ltd., Gilead Sciences Inc., NVIDIA Corporation, Amgen Inc., Novo Nordisk A/S, Merck KGaA, Biogen Inc., CareDx Inc., Clario Inc., BenevolentAI Limited, Recursion Pharmaceuticals Inc., Insilico Medicine Inc., and Genesis Therapeutics Inc.
A notable collaboration took place in February 2025 when Incyte Corporation, a US-based biopharmaceutical firm, teamed up with Genesis Therapeutics Inc. to harness AI's potential to boost drug development efficiency. This partnership combines Incyte's drug discovery knowledge with Genesis Therapeutics' proprietary AI platform aimed at accelerating the identification and refinement of innovative small molecule candidates targeting specific therapeutic areas. Genesis Therapeutics Inc. is a US-centered AI-driven biotech company committed to pioneering advancements in drug discovery through cutting-edge technologies.

Download a free sample of the ai in biotechnology market report:
https://thebusinessresearchcompany.com/sample_request?id=10166696&type=smp&name=AI%20In%20Biotechnology%20Market%20Report%202026&utm_source=OpenPR&utm_medium=paid&utm_campaign=Sep_PR

How Key Trends Are Reshaping the AI in Biotechnology Market
Leading companies in this sector are increasingly focusing on technological innovations such as AI-powered antibody discovery platforms, which enhance the speed and cost-effectiveness of therapeutic antibody development. These platforms leverage artificial intelligence to rapidly identify and optimize antibodies, improving drug discovery outcomes and reducing timelines.
For example, in February 2023, AION Labs, an Israeli venture studio, launched DenovAI, a platform designed for the de novo discovery of therapeutic antibodies. By combining machine learning with computational biophysics, DenovAI can identify high-affinity antibody candidates with greater precision and sequence diversity while significantly shortening development cycles. This platform represents a breakthrough in biotechnology, enabling faster and more economical discovery processes with better chances of clinical success across various diseases.

Essential Segments and Subcategories in the Global AI in Biotechnology Market
The AI in biotechnology market is broadly segmented by component, application, and end user.
By component, the market includes software, hardware, and services. Software subsegments feature AI-powered data analytics, machine learning algorithms, bioinformatics software, drug discovery platforms, and clinical trial management software. Hardware covers high-performance computing systems, AI-integrated imaging devices, data storage solutions, laboratory automation equipment, and wearable health monitors. Services encompass AI implementation and integration, consulting and training, cloud-based AI solutions, maintenance and support, and custom AI model development.
Application-wise, the market serves drug discovery and development, clinical trials and optimization, medical imaging, diagnostics, and other specialized uses. Regarding end users, it includes pharmaceutical companies, biotechnology firms, academic and research institutes, healthcare providers, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and other relevant stakeholders.

View the full ai in biotechnology market report:
https://thebusinessresearchcompany.com/report/ai-in-biotechnology-global-market-report?utm_source=OpenPR&utm_medium=paid&utm_campaign=Sep_PR

This comprehensive segmentation highlights the diversity within the AI in biotechnology market, reflecting its broad applicability and the evolving technological landscape.

Our 2026 reports feature deeper market intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.